黄金城集团

至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Anti-MET VHH Pool Overcomes MET-Targeted Cancer Therapeutic Resistance.

Mol. Cancer Ther.. 2019; 
SuZhipeng,HanYunchun,SunQichen,WangXiaoxiao,XuTing,XieWei,Huang
Products/Services Used Details Operation
Catalog Antibody After 12hrs, cells were individually treated with human HGF (Z03229, GenScript) at a final concentration of 100ng/mL, with or without 50μg/mL 5D5 mAb, anti-MET VHH pool TOP10MIX, and reassembled sub-groups 5G1-5G12 respectively (followed by 4G1-4G5, 3G1-3G4 and 2G1-2G3). Get A Quote

摘要

Receptor tyrosine kinase MET and its ligand hepatocyte growth factor (HGF) play crucial roles in many human malignancies. Numerous drugs have been developed against kinase center of MET or HGF-mediated activation; however, the outcomes in patients are not so promising. Increasing evidence show that MET has kinase-independent effects on tumorigenesis and dissemination, which explains the low efficacy in kinase inhibition-based strategy. VHH is the recombinant variable region of heavy-chain antibody. As a nanoscale antigen-binding unit, VHH has become an appealing drug candidate in cancer therapy. In our study, we choose a novel strategy to construct an anti-MET VHH pool against the whole ecto-domain of ... More

关键词